Evaluation of the incidence, predictors, risk assessment scores and outcomes of thromboembolism in a cohort of Egyptian NHL patients - Real World Experience.
ANC
NLR
PLR
Predictors
VTE
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
07 Aug 2024
07 Aug 2024
Historique:
received:
24
02
2024
accepted:
15
07
2024
medline:
7
8
2024
pubmed:
7
8
2024
entrez:
7
8
2024
Statut:
aheadofprint
Résumé
Non-Hodgkin's Lymphoma (NHL) is the most common subtype of lymphoma. The incidence of venous thromboembolism (VTE) in aggressive NHL was estimated recently to be 11%. Several risk assessment scores and factors are available to help identify cancer patients at risk for developing VTE. Patients with a pathologically confirmed diagnosis of NHL were identified at the Oncology Center of Mansoura University. The study included 777 patients: 719 with DLBCL-NOS, 26 with Anaplastic-B-cell, and 32 with T-cell-rich-NHL. Data were retrospectively collected from electronic medical records, including clinical, radiological, and laboratory information related to VTE and NHL. The median age at NHL diagnosis was 53 years, (range: 18-98). There was a male predominance, 51.4% of the cases. At initial lymphoma diagnosis, VTE was identified in 46 (5.9%) patients, and 61 (7.9%) patients experienced VTE while undergoing chemotherapy. According to logistic regression analysis, a PS (performance status) ≥ 2, bulky lesions, and mediastinal masses were significant predictors of VTE at presentation, with P-values of 0.022, 0.002, and < 0.001, respectively. Meanwhile, NHL patients who developed VTE during chemotherapy had significantly poorer PS, higher absolute neutrophilic counts (ANC), neutrophil/lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and lactate dehydrogenase (LDH) levels than lymphoma patients without VTE, with P-values of 0.003, 0.034, 0.049, 0.01 and 0.007, respectively, as determined by multivariate analysis. The ROC curve identified the cut-off values of 4.875 × 10
Identifiants
pubmed: 39110199
doi: 10.1007/s00277-024-05904-8
pii: 10.1007/s00277-024-05904-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 68(6):394–424
doi: 10.3322/caac.21492
Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. Ca Cancer J Clin 73(1):17–48
pubmed: 36633525
doi: 10.3322/caac.21763
Ibrahim AH, Shash E (2022) General Oncology Care in Egypt. Cancer in the Arab World: Springer Singapore Singapore; pp. 41–61
Chaudhari K, Rizvi S, Syed BA (2019) Non-hodgkin lymphoma therapy landscape. Nat Rev Drug Discov 18(9):663–664
pubmed: 31477855
doi: 10.1038/d41573-019-00051-6
Mukai M, Oka T (2018) Mechanism and management of cancer-associated thrombosis. J Cardiol 72(2):89–93
pubmed: 29588087
doi: 10.1016/j.jjcc.2018.02.011
Gussoni G, Foglia E, Frasson S, Casartelli L, Campanini M, Bonfanti M et al (2013) Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients. Thromb Res 131(1):17–23
pubmed: 23141845
doi: 10.1016/j.thromres.2012.10.008
Sørensen HT, Mellemkjær L, Steffensen FH, Olsen JH, Nielsen GL (1998) The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338(17):1169–1173
pubmed: 9554856
doi: 10.1056/NEJM199804233381701
Martens KL, Li A, La J, May SB, Swinnerton KN, Tosi H et al (2023) Epidemiology of Cancer-Associated venous thromboembolism in patients with solid and hematologic neoplasms in the Veterans Affairs Health Care System. JAMA Netw Open 6(6):e2317945–e
pubmed: 37306999
pmcid: 10261992
doi: 10.1001/jamanetworkopen.2023.17945
Sanfilippo K, Wang T, Gage B, Luo S, Riedell P, Carson K (2016) Incidence of venous thromboembolism in patients with non-hodgkin lymphoma. Thromb Res 143:86–90
pubmed: 27208462
pmcid: 4920731
doi: 10.1016/j.thromres.2016.05.008
Dharmavaram G, Cao S, Sundaram S, Ayyappan S, Boughan K, Gallogly M et al (2020) Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma-specific venous thrombosis prediction models. Am J Hematol 95(8):918–926
pubmed: 32311162
doi: 10.1002/ajh.25837
Elshoury A, Schaefer JK, Lim MY, Skalla DP, Streiff MB (2022) Update on guidelines for the prevention of cancer-associated thrombosis. J Natl Compr Canc Netw. ;20(13)
Koch A, Meesters MI, Scheller B, Boer C, Zacharowski K (2013) Systemic endotoxin activity correlates with clot formation: an observational study in patients with early systemic inflammation and sepsis. Crit Care 17(5):1–8
doi: 10.1186/cc12892
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood J Am Soc Hematol 111(10):4902–4907
Makgoeng SB, Bolanos RS, Jeon CY, Weiss RE, Arah OA, Breen EC et al (2018) Markers of immune activation and inflammation, and non-hodgkin lymphoma: a meta-analysis of prospective studies. JNCI cancer Spectr 2(4):pky082
pubmed: 30873511
doi: 10.1093/jncics/pky082
Otasevic V, Mihaljevic B, Milic N, Stanisavljevic D, Vukovic V, Tomic K et al (2022) Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients. Thromb J 20(1):1–10
doi: 10.1186/s12959-022-00381-3
Rupa-Matysek J, Gil L, Kroll‐Balcerzak R, Barańska M, Komarnicki M (2017) Mean platelet volume as a predictive marker for venous thromboembolism and mortality in patients treated for diffuse large B‐cell lymphoma. Hematol Oncol 35(4):456–464
pubmed: 27377517
doi: 10.1002/hon.2321
Rupa-Matysek J, Gil L, Barańska M, Dytfeld D, Komarnicki M (2018) Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma. Oncotarget 9(30):21190
pubmed: 29765530
pmcid: 5940371
doi: 10.18632/oncotarget.25002
Farah R, Nseir W, Kagansky D, Khamisy-farah R (2020) The role of neutrophil‐lymphocyte ratio, and mean platelet volume in detecting patients with acute venous thromboembolism. J Clin Lab Anal 34(1):e23010
pubmed: 31508844
doi: 10.1002/jcla.23010
Hohaus S, Bartolomei F, Cuccaro A, Maiolo E, Alma E, D’Alò F et al (2020) Venous thromboembolism in lymphoma: risk stratification and antithrombotic prophylaxis. Cancers 12(5):1291
pubmed: 32443753
pmcid: 7281118
doi: 10.3390/cancers12051291
Antic D, Milic N, Nikolovski S, Todorovic M, Bila J, Djurdjevic P et al (2016) Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. Am J Hematol 91(10):1014–1019
pubmed: 27380861
doi: 10.1002/ajh.24466
Pelzer U, Sinn M, Stieler J, Riess H (2013) Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy? Dtsch Med Wochenschr 138(41):2084–2088
pubmed: 24085361
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586
pubmed: 17242396
doi: 10.1200/JCO.2006.09.2403
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059
pubmed: 25113753
pmcid: 4979083
doi: 10.1200/JCO.2013.54.8800
Caruso V, Di Castelnuovo A, Meschengieser S, Lazzari MA, De Gaetano G, Storti S et al (2010) Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood J Am Soc Hematol 115(26):5322–5328
Lekovic D, Miljic P, Mihaljevic B (2010) Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma. Thromb Res 126(6):477–480
pubmed: 21126629
doi: 10.1016/j.thromres.2010.08.017
Yokoyama K, Murata M, Ikeda Y, Okamoto S (2012) Incidence and risk factors for developing venous thromboembolism in Japanese with diffuse large b-cell lymphoma. Thromb Res 130(1):7–11
pubmed: 22000981
doi: 10.1016/j.thromres.2011.09.022
Gerotziafas GT (2019) La maladie thromboembolique veineuse chez les patients atteints d’une hémopathie maligne État des lieux sur l’ampleur du problème. Hématologie. ;25(1)
Mahajan A, Wun T, Chew H, White RH (2014) Lymphoma and venous thromboembolism: influence on mortality. Thromb Res 133:S23–S8
pubmed: 24862141
doi: 10.1016/S0049-3848(14)50004-7
Kekre N, Connors JM (2019) Venous thromboembolism incidence in hematologic malignancies. Blood Rev 33:24–32
pubmed: 30262170
doi: 10.1016/j.blre.2018.06.002
Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH et al (2006) Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Official J Am Coll Gastroenterology| ACG 101(7):1524–1528
doi: 10.1111/j.1572-0241.2006.00588.x
Ambrosino P, Tarantino L, Di Minno G, Paternoster M, Graziano V, Petitto M et al (2017) The risk of venous thromboembolism in patients with cirrhosis. Thromb Haemost 26(01):139–148
doi: 10.1160/TH16-06-0450
Chen Y, Lei H, Wang W, Zhu J, Zeng C, Lu Z et al (2022) Characteristics and predictors of venous thromboembolism among Lymphoma patients undergoing chemotherapy: a Cohort Study in China. Front Pharmacol 13:901887
pubmed: 35677441
pmcid: 9168459
doi: 10.3389/fphar.2022.901887
Taalab MM, Shaaban YE (2023) Prognostic impact of pretreatment serum lactate dehydrogenase levels in adult patients with Acute myeloid leukemia: single Center experience. Benha Med J
Hohaus S, Massini G, Giachelia M, Vannata B, Bozzoli V, Cuccaro A et al (2010) Anemia in Hodgkin’s lymphoma: the role of interleukin-6 and hepcidin
Kim AS, Khorana AA, McCrae KR (2020) Mechanisms and biomarkers of cancer-associated thrombosis. Translational Res 225:33–53
doi: 10.1016/j.trsl.2020.06.012
Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 7:291–292
pubmed: 22547369
doi: 10.1007/s11739-012-0784-y
Di Nisio M, van Es N, Rotunno L, Anzoletti N, Falcone L, De Tursi M et al (2019) Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. J Thromb Thrombolysis 48:125–133
pubmed: 30919253
doi: 10.1007/s11239-019-01845-6
El-Sayed HA, Othman M, Azzam H, Bucciol R, Ebrahim MA, El-Agdar M et al (2023) Assessing the risk of venous thromboembolism in patients with haematological cancers using three prediction models. J Cancer Res Clin Oncol
Santi RM, Ceccarelli M, Bernocco E, Monagheddu C, Evangelista A, Valeri F et al (2017) Khorana score and histotype predicts incidence of early venous thromboembolism in non-hodgkin lymphomas. Thromb Haemost 117(08):1615–1621
doi: 10.1160/TH16-11-0895
Rupa-Matysek J, Gil L, Kaźmierczak M, Barańska M, Komarnicki M (2018) Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana risk score. Med Oncol 35:1–8
doi: 10.1007/s12032-017-1065-4
Borchmann S, Müller H, Hude I, Fuchs M, Borchmann P, Engert A (2019) Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials. Ann Oncol 30(8):1329–1334
pubmed: 31132094
doi: 10.1093/annonc/mdz168
Abdel-Razeq H, Ma’koseh M, Mansour A, Bater R, Amarin R, Abufara A et al (2021) The application of the ThroLy risk assessment model to predict venous thromboembolism in patients with diffuse large B-cell lymphoma. Clin Appl Thromb Hemost 27:10760296211045908
pubmed: 34590497
pmcid: 8642105
doi: 10.1177/10760296211045908
van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten H-M, Mahé I et al (2017) Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica 102(9):1494
pubmed: 28550192
pmcid: 5685240
doi: 10.3324/haematol.2017.169060
Rupa-Matysek J, Brzeźniakiewicz‐Janus K, Gil L, Krasiński Z, Komarnicki M (2018) Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice. Cancer Med 7(7):2868–2875
pubmed: 29761831
pmcid: 6051175
doi: 10.1002/cam4.1540
Romano A, Parrinello NL, Vetro C, Chiarenza A, Cerchione C, Ippolito M et al (2018) Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. Ann Hematol 97(6):1009–1018
pubmed: 29442162
doi: 10.1007/s00277-018-3276-y
Artoni A, Abbattista M, Bucciarelli P, Gianniello F, Scalambrino E, Pappalardo E et al (2018) Platelet to lymphocyte ratio and neutrophil to lymphocyte ratio as risk factors for venous thrombosis. Clin Appl Thromb Hemost 24(5):808–814
pubmed: 29088921
doi: 10.1177/1076029617733039
Li Y, Zhu Y, Duan X (2023) Prognostic value of multiple immune inflammatory markers in diffuse large B-cell lymphoma. Am J Translational Res 15(4):2610
Mohsen A, Taalab MM, Abousamra NK, Mabed M (2019) Prognostic significance of Absolute lymphocyte to Absolute Monocyte count ratio in Egyptian patients with relapsed diffuse large B-Cell lymphoma. Clin Lymphoma Myeloma Leuk 19:S252
doi: 10.1016/j.clml.2019.07.159
Samuelson Bannow BT, Konkle BA (2018) Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: a review. Thromb Res 163:138–145
pubmed: 29407626
doi: 10.1016/j.thromres.2018.01.037
Akdeniz A, Mehtap Ö, Karakuş V, Ünal S, Aygün K, Temel GÖ et al (2021) Are Platelet-related Parameters Predictive of the Prognosis of Hodgkin’s Lymphoma?
Xie S, Yu Z, Feng A, Zheng S, Li Y, Zeng Y et al (2022) Analysis and prediction of relative survival trends in patients with non-hodgkin lymphoma in the United States using a model-based period analysis method. Front Oncol 12:942122
pubmed: 36237337
pmcid: 9551310
doi: 10.3389/fonc.2022.942122
Gordon MJ, Duan Z, Zhao H, Nastoupil L, Ferrajoli A, Danilov AV et al (2023) A novel comorbidity score for older adults with non-hodgkin lymphoma: the 3-factor risk estimate scale. Blood Adv 7(11):2632–2642
pubmed: 36753602
pmcid: 10282013
doi: 10.1182/bloodadvances.2022009507